## MEDP: Medpace Holdings, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: PEG 3.59 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($525.07)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 4
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. Advisory Services Network LLC Sells 2,312 Shares of Medpace Holdings, Inc. $MEDP**
- Source: MarketBeat | 20251216T090931 | Somewhat-Bullish | Relevance: 100%
- Advisory Services Network LLC reduced its stake in Medpace Holdings, Inc. by 14.6%, selling 2,312 shares and holding 13,473 shares valued at approximately $4.23 million. This transaction occurred amidst notable insider selling from Medpace executives and recent positive earnings results that surpassed analyst expectations. Medpace (NASDAQ:MEDP) reported $3.86 EPS against an estimated $3.50, with revenues up 23.7% year-over-year, and has set strong FY2025 guidance.

**2. Barclays Maintains Medpace Holdings (MEDP) Underweight Recommendation**
- Source: Nasdaq | 20251216T120929 | Somewhat-Bearish | Relevance: 100%
- Barclays has maintained an Underweight recommendation for Medpace Holdings (MEDP). The average one-year price target for MEDP is $547.08/share, suggesting a 2.16% downside from its current closing price. Institutional ownership has seen some shifts, with Aqr Capital Management increasing its holdings while the total shares owned by institutions decreased by 9.05%.

**3. Texas Permanent School Fund Corp Buys 2,313 Shares of Medpace Holdings, Inc. $MEDP**
- Source: MarketBeat | 20251216T120929 | Somewhat-Bullish | Relevance: 100%
- Texas Permanent School Fund Corp increased its stake in Medpace Holdings, Inc. by 10% in the second quarter, adding 2,313 shares to reach a total of 25,359 shares, valued at approximately $7.96 million. This increase comes amidst significant insider selling, with top executives offloading shares worth over $233 million in the past three months. Despite mixed analyst ratings and a consensus "Hold" rating, Medpace exceeded Q3 earnings and revenue estimates and provided positive FY2025 guidance.

**4. Medpace price target raised to $525 from $485 at Barclays**
- Source: TipRanks | 20251215T122118 | Somewhat-Bullish | Relevance: 100%
- Barclays analyst Luke Sergott has increased the price target for Medpace (MEDP) to $525 from $485, while maintaining an Underweight rating. This adjustment is part of the firm's 2026 outlook for the life sciences and diagnostics tools sector, with the analyst suggesting a positive setup for outperformance in the tools group for 2026 due to anticipated market recovery and the sector being "most under-owned" in healthcare.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-15 | Barclays | $525 | $485 | +8% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-15 | Barclays | main | Underweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 5 ($0.82M) |
| Sells | 29 ($217.29M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 36.5% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Blackrock Inc.: 8.4% (-4.4%)
- Vanguard Group Inc: 8.1% (-4.5%)
- AQR Capital Manageme: 3.6% (+65.1%)
- Wasatch Advisors LP: 3.3% (-2.1%)
- State Street Corpora: 2.4% (-4.8%)

### Key Risks

1. Heavy insider selling: $217M sold (29 transactions in 90 days).
2. Valuation stretched: PEG 3.6x requires aggressive growth execution.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_10 improving +3.6% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 3.59 signals overvaluation risk, limited margin of safety. Forward P/E 33.7x stretched relative to 9% growth. Quality metrics strong (ROE 74%, ROA 16%, margin 18%). Analyst sentiment positive (1 raises, avg +8%). Insider selling cluster ($217.3M in 90 days), potential headwind. Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $15.7B |
| Beta | 1.43 |
| 52W Range | $250.05 - $626.25 |
| Short Interest | 6.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 3.59 |
| Forward P/E | 33.7 |
| Current P/E | 36.8 |
| YoY Growth | 9.2% |
| EPS Direction | RISING |

### Technicals

MRS_10 strengthening from -0.3% to 3.3% (+3.6% in 5 days), confirming momentum buildup. Currently in lower STRENGTH zone (3.0-6.0%), cross-sectional ranking at 63rd percentile. MRS_5 at 1.4% confirms short-term momentum alignment. Long-term uptrend intact (above SMA200 at 1.33x) but short-term weakness (below SMA20). MACD histogram bearish (-2.59), momentum weakening. RSI neutral at 43. OFD pattern: -SUL (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 3.34% (CS: 63) | Strong |
| RSI_14 | 43.3 | Neutral |
| MACD Histogram | -2.59 | Bearish |
| vs SMA20 | 0.969x | Below |
| vs SMA50 | 0.976x | Below |
| vs SMA200 | 1.328x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $557.07
- **Stop Loss:** $525.07 (5.7% risk)
- **Target:** $589.07 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 33
- **Position Value:** $18,383.31
- **Portfolio %:** 18.38%
- **Risk Dollars:** $1,080.00
- **Risk Per Trade:** 1.08%
- **Modifiers:** L1 90% | L2 120% | Combined 1.08x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | RISK_OFF (HIGH) | 0.90x |
| L2 Sector | TREND (Zone A) | 1.20x |

*RISK_OFF regime with deteriorating conditions. VIX rising to 17.6 (+11.7% over 5 days) signals increasing anxiety, while narrow breadth at 52.6% indicates selective participation. AI infrastructure cost concerns are pressuring tech leadership, creating sector rotation challenges in a late-cycle environment.*

### Earnings

**Next:** 2026-02-09 (Est: $4.21)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $3.57 | $3.86 | +8.1% |
| 2025Q2 | $3.00 | $3.10 | +3.5% |
| 2025Q1 | $3.07 | $3.67 | +19.6% |
| 2024Q4 | $3.12 | $3.68 | +18.1% |

---
*RULE-based L3 | 2026-01-07 01:40 | MRS_10*